| The IL-1 family in tumorigenesis and antitumor immunity R Sun, DS Gao, J Shoush, B Lu Seminars in cancer biology 86, 280-295, 2022 | 31 | 2022 |
| Development and application of sensitive, specific, and rapid CRISPR‐Cas13‐based diagnosis D Shihong Gao, X Zhu, B Lu Journal of Medical Virology 93 (7), 4198-4204, 2021 | 30 | 2021 |
| The half-life-extended IL21 can be combined with multiple checkpoint inhibitors for tumor immunotherapy S Wu, R Sun, B Tan, B Chen, W Zhou, DS Gao, J Zhong, H Huang, ... Frontiers in Cell and Developmental Biology 9, 779865, 2021 | 16 | 2021 |
| Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity R Sun, H Zhao, DS Gao, A Ni, H Li, L Chen, X Lu, K Chen, B Lu Science Advances 9 (34), eadd7399, 2023 | 6 | 2023 |
| Synergism between IL21 and anti-PD-1 combination therapy is underpinned by the coordinated reprogramming of the immune cellular network in the tumor microenvironment S Wu, H Huang, R Sun, DS Gao, F Ye, J Huang, E Li, A Ni, KGK Lu, ... Cancer research communications 3 (8), 1460-1472, 2023 | 3 | 2023 |
| Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses Y Li, DS Gao, L Yi, F Gao, R Sun, KK Lu, J Xu, J Shoush, Z Kykrou, ... bioRxiv, 2022.09. 11.507505, 2022 | | 2022 |
| Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33 DS Gao, Y Li, J Shoush, R Sun, B Lu Cancer Research 82 (12_Supplement), 1326-1326, 2022 | | 2022 |
